INBX Inhibrx Corp Earnings per share for the last twelve months

INBX (Inhibrx) - company brandmark

Inhibrx Biosciences (INBX) relies on outsourced development and manufacturing, which drives the net income per share dynamics over the last four quarters. The value -9.03 serves as the current mark for this metric. Market capitalization is based on the sale of therapies for rare diseases, while growth potential is supported by a robust R&D pipeline of innovative protein candidates in the field of oncology.

INBX (Inhibrx Biosciences) Net earnings per share for the last 12 months history from 07/04/2022 to 11/16/2026

Inhibrx Corp - analytical breakdowns and key metrics (INBX)

- current quotes and average value forecast:
Basic company analysis:inhibrx.com (INBX)
Mass-produced product of Inhibrx Biosciences Inc

Net income per share over 12 months measures the actual earnings attributable to a single share after accounting for all expenses and the volume of issuance, determining the business's fundamental margin of safety. Analyzing the earnings per share trend over the last four quarters allows for an assessment of Inhibrx Biosciences (INBX) resilience against colossal R&D expenditures and FDA clinical trial risks.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months i-mabbiopharma.com (IMAB)|Earnings per share for the last twelve months Fennec (FENC)|HRTX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Nuvectis NVCT|Coherus Biosciences - Earnings per share for the last twelve months|CRBP - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months cardiffoncology.com|BYSI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla, Inc. BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharmaceuticals, Inc. CTXR|Net earnings per share for the last 12 months CLRB (Cellectar Biosciences)|BLRX (BioLineRx) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea)|Kazia Therapeutics Limited - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (silexion.com)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months